Breakthrough T1D Encouraged by Results of Clinical Trial Demonstrating Effectiveness of Existing Drug in New-Onset Type 1 Diabetes
September 19, 2025
September 19, 2025
NEW YORK, Sept. 19 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:
* * *
Breakthrough T1D Encouraged by Results of Clinical Trial Demonstrating Effectiveness of Existing Drug in New-Onset Type 1 Diabetes
*
Low dose of immunosuppressant antithymocyte globulin (ATG) preserved beta cell function as measured by stimulated C-peptide
NEW YORK, Sept. 19, 2 . . .
* * *
Breakthrough T1D Encouraged by Results of Clinical Trial Demonstrating Effectiveness of Existing Drug in New-Onset Type 1 Diabetes
*
Low dose of immunosuppressant antithymocyte globulin (ATG) preserved beta cell function as measured by stimulated C-peptide
NEW YORK, Sept. 19, 2 . . .
